All In MedTech

FDA Clearance Tracker · K251245

OxyMinder Pro (10310)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Aug 11, 2025

Substantially Equivalent

Time to decision

111 days

Received Apr 22, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K251245
Device name
OxyMinder Pro (10310)
Applicant location
Guilford, CT
Received
Apr 22, 2025
Decided
Aug 11, 2025
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 868.1720

Every decision under product code CCL

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code CCL. The earliest in FDA's data is K760338, decided Aug 11, 1976.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Bio-Med Device, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.